In Brief: CellPro, Inc.
This article was originally published in The Gray Sheet
Executive Summary
Gains investigational device exemption clearance to commence clinical trials of its Ceprate B-cell depletion system in conjunction with its Ceprate SC stem cell concentration system for reducing the number of B-cells in mobilized peripheral blood used for autologous hemapoietic transplantation in patients with relapsed non-Hodgkin's lymphoma. Approximately 25 patients at the Ireland Cancer Center at University Hospitals of Cleveland, Case Western Reserve University and the University of Washington Medical Center are expected to participate in the trials, which will evaluate the safety and efficacy of B-cell purging combined with a CD34+ cell enrichment of mobilized peripheral blood. By purging lymphoma tumor cells from peripheral blood stem cell grafts, use of the system could prevent tumor cells from being returned to the patient...